Expected but great news for CBST. Probably our best trade of the year.
V1
--------------------------------------------------------------------------------
10/26 11:20A (DJ) +DJ Cubist Pharma: Cidecin Meets Efficacy Endpoint In Study
Story 4165 DJ Cubist Pharma/Cidecin -2: Success Ranged 65%-75% >CBST
LEXINGTON, Mass. (Dow Jones)--Cubist Pharmaceuticals Inc. (CBST) said
clinical results show the company's Cidecin, or daptomycin for injection,
works as well as current standards of therapy.
The company developed Cidecin for the treatment of complicated skin and soft
tissue infection caused by Gram-positive pathogens.
In a press release Friday, Cubist said it is hopeful Cidecin, should it
receive full Food & Drug Administration approval, will fill a need for novel
pharmaceutials to treat serious and life-threatening bacterial infections.
Patients in the second Phase III studies for were treated for 7 to 14 days
and randomly received Cidecin 4 mg/kg once daily, or a comparator, in which
investigators had the choice of vancomycin, given twice daily, or a
semi-synthetic penicillin, usually oxacillin, given four times daily.
The multi-center, randomized and double-blinded study enrolled 517 patients
between 18 to 85 years old, who had skin and soft tissue infections, caused by
Gram-positive bacteria, that required hospitalization.
In all groups analyzed, Cubist said, clinical success rates ranged between
65% and 75% for the Cidecin patients, versus 64% to 75%
Cubist shares of recently traded at $40.85, up 80 cents or 2%, on Nasdaq |
